A Study of Ultra High Dose Diuretics to Treat Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Heart Failure; With Decompensation
Interventions
DRUG

Bumetanide

Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.

DRUG

Furosemide

"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06036914 - A Study of Ultra High Dose Diuretics to Treat Heart Failure | Biotech Hunter | Biotech Hunter